Cargando…

Performance differences among commercially available antigen rapid tests for COVID-19 in Brazil

A rapid and accurate diagnosis is a crucial strategy for containing the coronavirus disease (COVID-19) pandemic. Considering the obstacles to upscaling the use of RT–qPCR, rapid tests based on antigen detection (Ag-RDT) have become an alternative to enhance mass testing, reducing the time for a prom...

Descripción completa

Detalles Bibliográficos
Autores principales: Freire, Mariana Lourenço, Alves, Lindicy Leidicy, de Souza, Carolina Senra, Saliba, Juliana Wilke, Faria, Verônica, Pedras, Mariana Junqueira, Carvalho, Nara de Oliveira, Andrade, Gláucia Queiroz, Rabello, Ana, Avelar, Daniel Moreira, Cota, Gláucia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9202877/
https://www.ncbi.nlm.nih.gov/pubmed/35709075
http://dx.doi.org/10.1371/journal.pone.0269997
_version_ 1784728605968826368
author Freire, Mariana Lourenço
Alves, Lindicy Leidicy
de Souza, Carolina Senra
Saliba, Juliana Wilke
Faria, Verônica
Pedras, Mariana Junqueira
Carvalho, Nara de Oliveira
Andrade, Gláucia Queiroz
Rabello, Ana
Avelar, Daniel Moreira
Cota, Gláucia
author_facet Freire, Mariana Lourenço
Alves, Lindicy Leidicy
de Souza, Carolina Senra
Saliba, Juliana Wilke
Faria, Verônica
Pedras, Mariana Junqueira
Carvalho, Nara de Oliveira
Andrade, Gláucia Queiroz
Rabello, Ana
Avelar, Daniel Moreira
Cota, Gláucia
author_sort Freire, Mariana Lourenço
collection PubMed
description A rapid and accurate diagnosis is a crucial strategy for containing the coronavirus disease (COVID-19) pandemic. Considering the obstacles to upscaling the use of RT–qPCR, rapid tests based on antigen detection (Ag-RDT) have become an alternative to enhance mass testing, reducing the time for a prompt diagnosis and virus spreading. However, the performances of several commercially available Ag-RDTs have not yet been evaluated in several countries. Here, we evaluate the performance of eight Ag-RDTs available in Brazil to diagnose COVID-19. Patients admitted to tertiary hospitals with moderate or mild COVID-19 symptoms and presenting risk factors for severe disease were included. The tests were performed using a masked protocol, strictly following the manufacturer’s recommendations and were compared with RT–qPCR. The overall sensitivity of the tests ranged from 9.8 to 81.1%, and specificity greater than 83% was observed for all the evaluated tests. Overall, slight or fair agreement was observed between Ag-RDTs and RT–PCR, except for the Ag-RDT COVID-19 (Acro Biotech), in which moderate agreement was observed. Lower sensitivity of Ag-RDTs was observed for patients with cycle threshold > 25, indicating that the sensitivity was directly affected by viral load, whereas the effect of the disease duration was unclear. Despite the lower sensitivity of Ag-RDTs compared with RT–qPCR, its easy fulfillment and promptness still justify its use, even at hospital admission. However, the main advantage of Ag-RDTs seems to be the possibility of increasing access to the diagnosis of COVID-19 in patients with a high viral load, allowing immediate clinical management and reduction of infectivity and community transmission.
format Online
Article
Text
id pubmed-9202877
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-92028772022-06-17 Performance differences among commercially available antigen rapid tests for COVID-19 in Brazil Freire, Mariana Lourenço Alves, Lindicy Leidicy de Souza, Carolina Senra Saliba, Juliana Wilke Faria, Verônica Pedras, Mariana Junqueira Carvalho, Nara de Oliveira Andrade, Gláucia Queiroz Rabello, Ana Avelar, Daniel Moreira Cota, Gláucia PLoS One Research Article A rapid and accurate diagnosis is a crucial strategy for containing the coronavirus disease (COVID-19) pandemic. Considering the obstacles to upscaling the use of RT–qPCR, rapid tests based on antigen detection (Ag-RDT) have become an alternative to enhance mass testing, reducing the time for a prompt diagnosis and virus spreading. However, the performances of several commercially available Ag-RDTs have not yet been evaluated in several countries. Here, we evaluate the performance of eight Ag-RDTs available in Brazil to diagnose COVID-19. Patients admitted to tertiary hospitals with moderate or mild COVID-19 symptoms and presenting risk factors for severe disease were included. The tests were performed using a masked protocol, strictly following the manufacturer’s recommendations and were compared with RT–qPCR. The overall sensitivity of the tests ranged from 9.8 to 81.1%, and specificity greater than 83% was observed for all the evaluated tests. Overall, slight or fair agreement was observed between Ag-RDTs and RT–PCR, except for the Ag-RDT COVID-19 (Acro Biotech), in which moderate agreement was observed. Lower sensitivity of Ag-RDTs was observed for patients with cycle threshold > 25, indicating that the sensitivity was directly affected by viral load, whereas the effect of the disease duration was unclear. Despite the lower sensitivity of Ag-RDTs compared with RT–qPCR, its easy fulfillment and promptness still justify its use, even at hospital admission. However, the main advantage of Ag-RDTs seems to be the possibility of increasing access to the diagnosis of COVID-19 in patients with a high viral load, allowing immediate clinical management and reduction of infectivity and community transmission. Public Library of Science 2022-06-16 /pmc/articles/PMC9202877/ /pubmed/35709075 http://dx.doi.org/10.1371/journal.pone.0269997 Text en © 2022 Freire et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Freire, Mariana Lourenço
Alves, Lindicy Leidicy
de Souza, Carolina Senra
Saliba, Juliana Wilke
Faria, Verônica
Pedras, Mariana Junqueira
Carvalho, Nara de Oliveira
Andrade, Gláucia Queiroz
Rabello, Ana
Avelar, Daniel Moreira
Cota, Gláucia
Performance differences among commercially available antigen rapid tests for COVID-19 in Brazil
title Performance differences among commercially available antigen rapid tests for COVID-19 in Brazil
title_full Performance differences among commercially available antigen rapid tests for COVID-19 in Brazil
title_fullStr Performance differences among commercially available antigen rapid tests for COVID-19 in Brazil
title_full_unstemmed Performance differences among commercially available antigen rapid tests for COVID-19 in Brazil
title_short Performance differences among commercially available antigen rapid tests for COVID-19 in Brazil
title_sort performance differences among commercially available antigen rapid tests for covid-19 in brazil
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9202877/
https://www.ncbi.nlm.nih.gov/pubmed/35709075
http://dx.doi.org/10.1371/journal.pone.0269997
work_keys_str_mv AT freiremarianalourenco performancedifferencesamongcommerciallyavailableantigenrapidtestsforcovid19inbrazil
AT alveslindicyleidicy performancedifferencesamongcommerciallyavailableantigenrapidtestsforcovid19inbrazil
AT desouzacarolinasenra performancedifferencesamongcommerciallyavailableantigenrapidtestsforcovid19inbrazil
AT salibajulianawilke performancedifferencesamongcommerciallyavailableantigenrapidtestsforcovid19inbrazil
AT fariaveronica performancedifferencesamongcommerciallyavailableantigenrapidtestsforcovid19inbrazil
AT pedrasmarianajunqueira performancedifferencesamongcommerciallyavailableantigenrapidtestsforcovid19inbrazil
AT carvalhonaradeoliveira performancedifferencesamongcommerciallyavailableantigenrapidtestsforcovid19inbrazil
AT andradeglauciaqueiroz performancedifferencesamongcommerciallyavailableantigenrapidtestsforcovid19inbrazil
AT rabelloana performancedifferencesamongcommerciallyavailableantigenrapidtestsforcovid19inbrazil
AT avelardanielmoreira performancedifferencesamongcommerciallyavailableantigenrapidtestsforcovid19inbrazil
AT cotaglaucia performancedifferencesamongcommerciallyavailableantigenrapidtestsforcovid19inbrazil